|
|
Volumn 112, Issue 13, 2005, Pages 2043-2046
|
|
Report from the cardiovascular and renal drugs Advisory Committee: US Food and Drug Administration; June 15-16, 2005; Gaithersburg, Md
|
|
Author keywords
Drugs; Heart failure; Hypertension
|
|
Indexed keywords
ANGIOTENSIN RECEPTOR ANTAGONIST;
ANTIHYPERTENSIVE AGENT;
CALCIUM CHANNEL BLOCKING AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DIURETIC AGENT;
ENALAPRIL;
HYDRALAZINE;
NITRATE;
PLACEBO;
PRAZOSIN;
AFRICAN AMERICAN;
BLOOD PRESSURE REGULATION;
CARDIOVASCULAR DISEASE;
CAUCASIAN;
CONFERENCE PAPER;
CONGESTIVE HEART FAILURE;
DRUG EFFICACY;
DRUG LABELING;
DRUG SURVEILLANCE PROGRAM;
FOOD AND DRUG ADMINISTRATION;
HEALTH CARE POLICY;
HEART INFARCTION;
HUMAN;
HYPERTENSION;
KIDNEY DISEASE;
POPULATION RESEARCH;
PRIORITY JOURNAL;
STROKE;
UNITED STATES;
AFRICAN CONTINENTAL ANCESTRY GROUP;
ANTIHYPERTENSIVE AGENTS;
CARDIOVASCULAR AGENTS;
DRUG COMBINATIONS;
DRUG LABELING;
EPIDEMIOLOGIC MEASUREMENTS;
HEART FAILURE, CONGESTIVE;
HUMANS;
HYDRALAZINE;
HYPERTENSION;
NITRATES;
PEDIATRICS;
RENAL AGENTS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 25444497043
PISSN: 00097322
EISSN: None
Source Type: Journal
DOI: 10.1161/CIRCULATIONAHA.105.573105 Document Type: Conference Paper |
|
Times cited : (12)
|
|
References (0)
|
